Cardiovascular outcomes in patients with bullous pemphigoid on rituximab compared to those on systemic corticosteroids: A propensity - matched retrospective study using the TriNetX database
Description
Supplemental materials as study methods and results. Figure S1. The study flowchart Table S1. Baseline characteristics of study subjects (before and after PSM matching) Table S2. Risk of Cardiovascular Outcomes in Patients with Bullous Pemphigoid Treated with Rituximab vs Steroids, Stratified by Duration of Follow-Up Table S3. Case number and Risk of Cardiovascular Outcomes in Patients With Bullous Pemphigoid Treated With Rituximab vs Steroids,(1 day to 1 year) Table S4. Risk of outcome (1 day to 1 year) PSM with different variables Table S5. Steroids used in this study: Detailed study design and data source are included in the supplementary file
Files
Steps to reproduce
This retrospective cohort study used de-identified electronic health records from the TriNetX US Collaborative Network, comprising data from 92 healthcare organizations. Between January 1, 2016, and December 31, 2023, of the 19,589 patients with BP, we identified comparable matched groups of 597 rituximab-treated and 597 steroid-treated patients—approximately 6% of the BP patient records—using 1:1 propensity score matching (PSM) for demographics, comorbidities, and healthcare utilization (Supplementary Tables 1 and 2). Outcomes, including VTE, myocardial infarction (MI), stroke, and infections, were evaluated up to one year after treatment initiation. Analyses used the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnoses (Supplementary Appendix).